The Company will perform studies in mouse models in collaboration with Professor Linda Hildegaard Bergersen at the University of Oslo. These studies will define the dose of the novel DYRK1A inhibitor development...

The Company has received support from the Regional Research Council to perform studies on mouse models of dementia.

A link to the presentation is here: https://www.youtube.com/watch?v=Yhs5FpkszyQ

The full article is available to download here: https://www.mdpi.com/1424-8247/14/11/1170/htm

The 12 most promising healthcare startups and scaleups will be presenting themselves to investors and potential partners at the DNB Healthcare Venture Session December 16, 2021. 

Pharmasum Therapeutics announces that the Company has moved into offices at the Oslo Science Park.

The Board approved the selection of development candidate and back-up for further progression into scale-up and GLP tox/safety.

Pharmasum Therapeutics AS announces the granting and publishing of its US patent covering composition of matter claims, relating to the Company’s ongoing DYRK1A inhibitor program.

At the Extraordinary General Assembly, Pharmasum Therapeutics AS declares that its shares shall be entered into the Euronext Share registry (formerly known as VPS).

At the Annual General Assembly, Dr. Reijo Salonen, MD, PhD and Dr. Anders Fugelli, PhD were elected to the Board of Directors of Pharmasum Therapeutics. At the same time, the Company closed a significant funding...

An in-depth interview and corresponding Podcast are available (in Norwegian).

Click here to read article: